Tag Archives: NSI-566

NeuralStem and the ‘Right-To Try’

Colorado has recently passed ‘Right-to-Try’ (RTT) legislation permitting companies to offer experimental treatments for fatal diseases that have not been FDA approved—and the requirement of payment is permitted if the Company so chooses. The criterion is that they have reached … Continue reading

Posted in BioFollies, Biotech, Muddled Media | Tagged , , , | Leave a comment